Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis
Authors:
- Ornela SulejmaniOrnela Sulejmani
- Laura GrunewaldLGLaura Grunewald
- Lena AnderschLALena Andersch
- Silke SchwiebertSSSilke Schwiebert
- Anika KlausAKAnika Klaus
- Annika WinklerAWAnnika Winkler
- Kathy AstrahantseffKAKathy Astrahantseff
- Angelika EggertAEAngelika Eggert
- Anton G. HenssenAHAnton G. Henssen
- Johannes H. SchulteJSJohannes H. Schulte
- Kathleen AndersKAKathleen Anders
- Annette KünkeleAKAnnette Künkele
Open Access
Abstract
Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising treatment strategy, however, therapeutic success against solid tumors such as neuroblastoma remains modest. Recurrence of antigen-poor tumor variants often ultimately results in treatment failure. Using antigen-independent killing mechanisms such as the FAS receptor (FAS)-FAS ligand (FASL) axis through epigenetic manipulation may be a way to counteract the escape achieved by antigen downregulation. Analysis of public RNA-sequencing data from primary neuroblastomas revealed that a particular epigenetic modifier, the histone lysine demethylase 1A (KDM1A), correlated negatively with FAS expression. KDM1A is known to interact with TP53 to repress TP53-mediated transcriptional activation of genes, including FAS. We showed that pharmacologically blocking KDM1A activity in neuroblastoma cells with the small molecule inhibitor, SP-2509, increased FAS cell-surface expression in a strictly TP53-dependent manner. FAS upregulation sensitized neuroblastoma cells to FAS-FASL-dependent killing and augmented L1CAM-directed CAR T cell therapy against antigen-poor or even antigen-negative tumor cells in vitro. The improved therapeutic response was abrogated when the FAS-FASL interaction was abolished with an antagonistic FAS antibody. Our results show that KDM1A inhibition unleashes an antigen-independent killing mechanism via the FAS-FASL axis to make tumor cell variants that partially or totally suppress antigen expression susceptible to CAR T cell therapy.Keywords
Funding Information
- Deutsche Krebshilfe (70112951)
This publication has 63 references indexed in Scilit:
- Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblastsCell Death & Disease, 2013
- NeuroblastomaSeminars in Pediatric Surgery, 2012
- Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification statusBMC Medical Genomics, 2011
- Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2Journal of the American Chemical Society, 2010
- A robust method for estimating gene expression states using Affymetrix microarray probe level dataBMC Bioinformatics, 2010
- High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed NeuroblastomaClinical Cancer Research, 2010
- Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for TherapyCancer Research, 2009
- Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinomaThe Journal of Pathology, 2003
- Epigenetic changes in tumor Fas levels determine immune escape and response to therapyCancer Cell, 2002
- Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas MoleculeScience, 1994